According to a report by Intel Market Research, the global Artemether API Market was valued at USD 78.0 million in 2025 and is estimated to reach USD 82.0 million in 2026, before growing to USD 112.0 million by 2034 at a CAGR of 3.97% during 2026–2034. Artemether is an artemisinin derivative used predominantly with lumefantrine in oral artemisinin-based combination therapies (ACTs), with a smaller injectable role in severe malaria. Market demand is closely connected to malaria incidence, public-health procurement and the continued use of quality-assured artemether/lumefantrine products.

Explore the full report: https://www.intelmarketresearch.com/levonorgestrel-api-market-64519

Why Is Demand Increasing

• Persistent malaria burden — WHO estimated 282 million malaria cases in 2024, creating an underlying demand base for artemether-based treatment and API procurement.

• Continued ACT use — The standard 20 mg/120 mg artemether/lumefantrine tablet and dispersible form remain on the 2025 WHO Model List of Essential Medicines, supporting their role as a major downstream route for artemether API demand.

• Pediatric treatment requirements — Dispersible 20 mg/120 mg tablets support child-friendly ACT dosing, while children bear a disproportionate mortality burden in Africa.

Antimalarial API & Public-Health Supply Watch

The Artemether API industry is closely linked to public-health procurement, quality-assured ACT supply and manufacturing capabilities across major producing regions. The report identifies Asia-Pacific as the leading API production region, while the WHO African Region dominates treatment demand. Quality assurance is an important commercial consideration, with WHO-prequalified API suppliers including Calyx, KPC, Mangalam, Matrix and Olon. Technical differentiation is also emerging through particle engineering: milled or particle-controlled grades can support dissolution and high-volume tablet processing. At the finished-product level, Quality Chemical Industries received WHO prequalification for a 20 mg/120 mg artemether/lumefantrine tablet in August 2026, expanding quality-assured ACT supply.

Segmentation Highlights

• By Type: Standard API and Milled/Particle-Controlled API. Standard API is identified as the largest type and serves as the core grade for ACT and injection products, while milled or particle-controlled API supports formulation and dissolution requirements.

• By Application: Uncomplicated Malaria ACT, Severe Malaria Injection and Pediatric Malaria Treatment. Uncomplicated malaria ACT is the largest application, reflecting the primary use of artemether/lumefantrine combinations.

• By Formulation Destination: Artemether/Lumefantrine Tablets, Dispersible Pediatric Tablets, Oily Injection and Other Combination Products. Artemether/lumefantrine tablets represent the main downstream API destination.

• By Customer Type: Global Health/FPP Manufacturers, Generic Antimalarial Manufacturers and Institutional Manufacturers. Global health and finished-pharmaceutical-product manufacturers represent major public-health procurement buyers.

• By Procurement Model: Global Health/Long-Term Procurement, Direct Manufacturer Contracts and Distributor/Tender Procurement. Global health and long-term procurement is identified as the largest channel.

• By Regulatory Destination: WHO-Prequalified/Highly Regulated Markets and Malaria-Endemic & Other Regulated Markets. Multi-market dossiers can increase plant utilization and customer retention.

Regional Outlook

• Asia-Pacific leads Artemether API production, with WHO-prequalified suppliers including Calyx, KPC, Mangalam and Matrix identified in the region.

• Middle East & Africa dominates consumption. The WHO African Region recorded 265 million cases and 579,000 deaths in 2024 according to the report.

• Europe has low disease burden but maintains strategic regulated API capability through suppliers such as Olon, which lists standard and milled WHO-prequalified artemether.

• Latin America has demand concentrated in endemic areas and country-specific malaria programs, with ACT procurement influenced by national policy and parasite species mix.

• North America has very small treatment volumes outside travel and imported malaria, with API demand primarily embedded in regulated global supply chains.

Download the free sample report: https://www.intelmarketresearch.com/download-free-sample/64519/levonorgestrel-api-market

Why This Market Matters

The Artemether API Market is tied directly to the continuing need for malaria treatment and the structure of global ACT procurement. Artemether/lumefantrine remains a major oral ACT architecture, while dispersible pediatric formulations provide a child-friendly treatment route. Because public-health programs and donor channels influence annual volumes, procurement structures can have a direct impact on API demand and supplier relationships.

The market also illustrates how technical quality and regulatory credentials can influence API sourcing. Controlled particle characteristics can provide formulation value, while light and heat sensitivity require appropriate storage and protective packaging. WHO prequalification represents an important commercial credential, and multi-source procurement allows buyers to work with qualified suppliers while maintaining supply continuity. At the same time, competition among ACT regimens, public-procurement pricing and antimalarial resistance can constrain price-led market expansion.

Competitive Landscape

• Calyx Chemicals & Pharmaceuticals — Offers WHO-prequalified standard artemether, including a below-25°C grade listed by WHO.

• Mangalam Drugs and Organics — Identified as a long-standing antimalarial API supplier.

• Matrix Pharmacorp — Has WHO-prequalified artemether, with a current 2025 confirmation identified in the report.

• Olon — Offers both standard and milled artemether API grades, highlighting particle engineering as a technical differentiator.

• KPC Pharmaceuticals — Identified as a quality-assured standard artemether source.

View the full report: https://www.intelmarketresearch.com/levonorgestrel-api-market-64519

FAQ

Q: What is the Artemether API Market size and forecast?

A: The market was valued at USD 78.0 million in 2025, is estimated at USD 82.0 million in 2026 and is projected to reach USD 112.0 million by 2034 at a CAGR of 3.97% during 2026–2034.

Q: Which regions lead supply and demand?

A: Asia-Pacific leads API production, while the WHO African Region drives the largest share of treatment demand.

Q: What is the main formulation driving Artemether API demand?

A: Artemether/lumefantrine tablets represent the dominant commercial formulation destination, with dispersible pediatric tablets also having high public-health relevance.

What Does the Full Report Cover?

The full Artemether API Market report goes beyond the headline Market Size and Growth Forecast to examine the supply, demand and regulatory factors shaping the industry through 2034. It covers six segmentation dimensions: Type, Application, Formulation Destination, Customer Type, Procurement Model and Regulatory Destination. The study also examines five major regions, including manufacturing concentration, treatment demand and procurement structures. Readers can explore supplier positioning, WHO prequalification, manufacturing capabilities, particle-controlled grades, regulatory requirements and source qualification. The report further examines public procurement, pediatric access, ACT competition, resistance concerns, formulation requirements and recent developments involving WHO-prequalified API and finished-product supply. This broader coverage provides context for understanding how technical, regulatory and public-health factors influence the Artemether API market outlook.

View the complete report: https://www.intelmarketresearch.com/levonorgestrel-api-market-64519

Download the free sample: https://www.intelmarketresearch.com/download-free-sample/64519/levonorgestrel-api-market

About Intel Market Research

Intel Market Research provides quantified market research and strategic intelligence across industries, covering market sizing, forecasting, segmentation, competitive analysis, regional assessment and industry developments. The company states that its reports combine primary interviews with structured analysis of named secondary sources, with market estimates subjected to validation before publication.

Contact Details

Website: www.intelmarketresearch.com | Asia-Pacific: +91 9169164321 | Email: help@intelmarketresearch.com.